Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area

European Neuropsychopharmacology

Volumn 22, Issue 7, 2012, Pages 501-505

  Leucht, Stefan ^a   Engel, Rolf R ^b   Davis, John M ^c   Kissling, Werner ^a   Meyer zur Capellen, Katrin ^e   Schmauß, Max ^d   Messer, Thomas ^e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d District Hospital Augsburg   (Germany)

^e Danuvius Klinik GmbH   (Germany)

Author keywords

Antipsychotic; Brief Psychiatric Rating Scale; Equipercentile linking; Schizophrenia

Indexed keywords

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; BRIEF PSYCHIATRIC RATING SCALE; CATCHMENT AREA (HEALTH); FEMALE; HUMANS; MALE; MENTAL DISORDERS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84861482379     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.11.007     Document Type: Article

References (19)

1. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ No. ADM 76-338) 1976, 218-222. National Institute of Mental Health, Rockville, MD.
2. Hofer A., Hummer M., Huber R., Kurz M., Walch T., Fleischhacker W.W. Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol. 2000, 20:699-702.
3. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-275.
4. Kolen M.J., Brennan R.L. Test equating. Methods and practices 1995, Springer, New York.
5. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. Clinical implications of BPRS scores. Br. J. Psychiatry 2005, 187:363-371.
6. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79:231-238.
7. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31:2318-2325.
8. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32:1903-1910.
9. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. Suppl. 2009, 7-14.
10. Levine S.Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 2008, 98:318-322.
11. Linn R.L. Linking results of distinct assessments. Appl. Meas. Educ. 1993, 6:83-102.
12. Nierenberg A.A., DeCecco L.M. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J. Clin. Psychiatry. 2002, 62:5-9. (suppl.).
13. Obermeier M., Mayr A., Schennach-Wolff R., Seemuller F., Moller H.J., Riedel M. Should the PANSS be rescaled?. Schizophr. Bull. 2010, 36:455-460.
14. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:790-812.
15. Rabinowitz J., Mehnert A., Eerdekens M. To what extent do the PANSS and CGI-S overlap?. J. Clin. Psychopharmacol. 2006, 26:303-307.
16. Rabinowitz J., Levine S.Z., Barkai O., Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr. Bull. 2009, 35:775-788.
17. Rabinowitz J., Levine S., Martinez G. Concordance between measures of functioning, symptoms, and change examining the GAF, CGI-S, CGI-C, and PANSS. J. Clin. Psychopharmacol. 2010, 30:478-480.
18. Riedel M., Strassnig M., Muller N., Zwack P., Moller H.J. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:143-148.
19. Schennach-Wolff R., Obermeier M., Seemuller F., Jager M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkotter J., Heuser I., Maier W., Lemke M.R., Ruther E., Klingberg S., Gastpar M., Engel R.R., Moller H.J., Riedel M. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J. Clin. Psychopharmacol. 2010, 30:726-731.